In a high-stakes diplomatic intervention aimed at safeguarding future global health security, Brazilian President Luiz Inácio Lula da Silva and World Health Organization (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus have issued a joint appeal to the leaders of the G7, G20, BRICS, and all sovereign nations. The leaders, writing from Brasília and Geneva respectively, have called for the immediate finalization of the Pathogen Access and Benefit-Sharing (PABS) annex, described as the "last piece of the puzzle" required to operationalize the historic WHO Pandemic Agreement. This call to action comes ahead of a critical negotiating session scheduled for July 6 to 17, which proponents hope will finally codify the lessons learned from the devastating COVID-19 pandemic.
The joint statement emphasizes that while the world successfully adopted the overarching Pandemic Agreement a year ago, the mechanism for sharing genetic materials of dangerous pathogens remains unfinished. Without this technical and legal framework, the international community remains vulnerable to the same inequities and delays that characterized the global response to SARS-CoV-2. The appeal outlines three specific demands: the exercise of high-level political will, a commitment to operational equity, and an absolute sense of urgency given the increasing probability of another zoonotic spillover event.
The Pathogen Access and Benefit-Sharing (PABS) Framework
At the heart of the current diplomatic deadlock is the PABS system. This framework is designed to create a "fair bargain" between nations. Under its provisions, countries that identify and share the genetic information of potentially pandemic-level pathogens must be guaranteed equitable access to the medical countermeasures—such as diagnostic tests, antiviral treatments, and vaccines—that are developed using that data.
During the COVID-19 pandemic, the world witnessed a phenomenon often described as "vaccine apartheid," where high-income nations secured the vast majority of early vaccine supplies, leaving developing nations in the Global South to wait months or years for protection. President Lula and Dr. Tedros argue that PABS is not an act of charity but a strategic necessity. By ensuring that resources are available where an outbreak begins, the global community can contain threats at their source, preventing localized epidemics from escalating into global catastrophes.
The system aims to replace the current ad hoc, case-by-case negotiations that occur during crises with a stable, predictable framework. This would provide laboratories and pharmaceutical partners with the legal certainty needed to move at the speed required by a rapidly spreading virus. For the PABS annex to be effective, however, the joint letter insists that equity must be embedded in its "operational detail," rather than relegated to the preamble of the agreement.
A Chronology of the Pandemic Agreement Negotiations
The journey toward a global pandemic treaty began in the wake of the catastrophic losses of 2020 and 2021. The following timeline outlines the key milestones leading to the current July deadline:
- May 2021: During the 74th World Health Assembly, Member States discussed the need for a new international instrument to strengthen pandemic prevention, preparedness, and response.
- December 2021: A Special Session of the World Health Assembly established an Intergovernmental Negotiating Body (INB) to draft and negotiate a WHO convention, agreement, or other international instrument.
- 2022–2023: The INB held multiple rounds of meetings, navigating complex debates over intellectual property, technology transfer, and financing.
- May 2024: At the 77th World Health Assembly, nations reaffirmed their commitment to the Pandemic Agreement but acknowledged that the PABS annex required further negotiation. Brazil’s G20 presidency played a pivotal role in highlighting inequality as a primary driver of pandemic vulnerability.
- May 1, 2024: Negotiators concluded a session with significant progress but failed to reach a final consensus on benefit-sharing percentages and governance structures.
- July 6–17, 2024: The upcoming session is viewed by the WHO and the Brazilian presidency as the definitive window to close the remaining gaps.
The Human and Economic Toll of Unpreparedness
The urgency of the appeal is underscored by the staggering data resulting from the COVID-19 pandemic. According to WHO estimates, the true death toll of the pandemic likely reached 20 million lives, far exceeding the official reported figures. Beyond the human loss, the International Monetary Fund (IMF) has estimated that the pandemic cost the global economy over $13 trillion in lost output.
The joint letter highlights that these losses were not merely financial; they manifested in broken supply chains, shuttered small businesses, and a generation of children who suffered from disrupted schooling. In contrast, the investment required to maintain a global surveillance and response system like PABS is a fraction of the cost of a full-scale pandemic.
Currently, the world is monitoring several high-risk situations, including an Ebola outbreak across two countries where responders are working without approved vaccines or cures. These "on-the-ground" realities serve as a stark reminder that the window of opportunity to prepare for the next threat is closing. Epidemiological models currently suggest a nearly 25% chance of another pandemic-scale event occurring within the next decade, driven by accelerating environmental and technological factors.
Addressing Concerns Over National Sovereignty
A significant hurdle in the ratification of the Pandemic Agreement has been the spread of misinformation regarding its impact on national sovereignty. Critics in several nations have claimed that the agreement would grant the WHO the power to impose lockdowns, mandate vaccinations, or override domestic laws.
President Lula and Dr. Tedros addressed these concerns directly, citing Article 22, paragraph 2 of the agreement. The text explicitly states that the WHO has no authority to direct or alter a country’s internal policies or laws. Decisions regarding travel restrictions, clinical mandates, and public health measures remain the exclusive prerogative of sovereign states. The PABS annex, as an integral part of the agreement, follows this principle, serving as a cooperative framework rather than a supranational mandate. The leaders have urged heads of government to instruct their negotiators to "reach for consensus with courage rather than caution," reassuring them that the agreement strengthens rather than diminishes national independence by providing tools that no single nation can develop alone.
Environmental and Technological Drivers of Future Risks
The appeal to world leaders also draws attention to the changing landscape of biological threats. The traditional assumption that dangerous pathogens only emerge in "distant" or tropical locations is increasingly being challenged by scientific data.
Climate change is altering the migratory patterns of wildlife and the geographical range of disease vectors like mosquitoes and ticks. Concurrently, changing land-use patterns and the intensification of agriculture are bringing human populations into closer contact with wild species, increasing the frequency of zoonotic spillover.
Furthermore, the joint statement notes that advances in biotechnology, while offering immense potential for medicine, also carry risks. If not matched by rigorous international biosafety standards, the accidental or deliberate release of engineered pathogens becomes a viable threat. These factors mean that future pandemic "hotspots" could just as easily emerge in the heart of the Global North as in the Global South, making universal participation in the PABS system a matter of self-interest for every nation.
Broader Implications and the Path Forward
The successful finalization of the PABS annex would represent a landmark achievement in international law and public health. It would build upon a legacy of global cooperation that includes the eradication of smallpox, the near-elimination of polio, and the coordinated fight against HIV, tuberculosis, and malaria.
The joint appeal from Brasília and Geneva frames the completion of the Pandemic Agreement as the "natural next chapter" of this legacy. By setting July 17 as a firm deadline, President Lula and Dr. Tedros are attempting to move the negotiations out of the realm of technical minutiae and into the realm of high-level political priority.
As negotiators prepare to convene in July, the eyes of the international community are on the G7, G20, and BRICS nations. These blocs represent the majority of the world’s economic power and pharmaceutical manufacturing capacity. Their leadership—or lack thereof—will determine whether the "spirit of equity" mentioned in the letter becomes a functional reality or remains a rhetorical aspiration. The finalization of this agreement is presented not just as a policy goal, but as a moral obligation to the millions lost to COVID-19 and a promise to protect future generations from a similar fate.
